We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.64B
AUM Growth
+$102M
Cap. Flow
-$45.8M
Cap. Flow %
-2.79%
Top 10 Hldgs %
45.39%
Holding
76
New
16
Increased
22
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$54.8M
2
CNC icon
Centene
CNC
+$30.1M
3
ARRY
Array Biopharma Inc
ARRY
+$27.2M
4
EW icon
Edwards Lifesciences
EW
+$23.9M
5
ELGX
Endologix Inc
ELGX
+$21.5M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$48.4M
2
INCY icon
Incyte
INCY
+$41.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$29.9M
4
IMMU
Immunomedics Inc
IMMU
+$21.9M
5
PTHN
Patheon N.V.
PTHN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Financials 1.4%
3 Communication Services 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPNC
26
DELISTED
Spectranetics Corp
SPNC
$24.4M 1.48%
634,802
+77,613
+14% +$2.24M
EHTH icon
27
eHealth
EHTH
$44.8M
$23M 1.4%
1,223,334
+32,000
+3% +$511K
CMRX
28
DELISTED
Chimerix, Inc.
CMRX
$22.9M 1.4%
4,207,575
-117,480
-3% -$618K
ICUI icon
29
ICU Medical
ICUI
$3.93B
$22.9M 1.39%
132,505
-28,038
-17% -$4.5M
LJPC
30
DELISTED
La Jolla Pharmaceutical Company
LJPC
$21.2M 1.29%
713,280
+108,810
+18% +$3.12M
IRTC icon
31
iRhythm Holdings
IRTC
$3.49B
$20.2M 1.23%
+476,341
New +$17.3M
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$18.6M 1.13%
367,537
-32,463
-8% -$1.38M
VRTX icon
33
Vertex Pharmaceuticals
VRTX
$120B
$18.6M 1.13%
+144,408
New +$17.4M
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$17.3M 1.05%
631,283
-303,060
-32% -$9.02M
NDRM
35
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$16.6M 1.01%
555,096
-369,208
-40% -$9.56M
NXTM
36
DELISTED
NxStage Medical Inc.
NXTM
$16.5M 1%
+657,356
New +$16.3M
JNCE
37
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$16M 0.97%
1,138,370
+24,210
+2% +$518K
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.7M 0.95%
97,326
+2,052
+2% +$322K
NSTG
39
DELISTED
NanoString Technologies, Inc.
NSTG
$14.3M 0.87%
866,819
-67,605
-7% -$1.19M
CLVS
40
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$14.2M 0.87%
+152,000
New +$9.3M
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
$13.9M 0.84%
3,735,994
-336,430
-8% -$1.33M
LIVN icon
42
LivaNova
LIVN
$4.3B
$13M 0.79%
+212,028
New +$12M
MODN
43
DELISTED
MODEL N, INC.
MODN
$11.4M 0.69%
858,314
+36,000
+4% +$431K
CTMX icon
44
CytomX Therapeutics
CTMX
$725M
$10.8M 0.66%
698,392
+16,500
+2% +$249K
PBYI icon
45
CALL
Puma Biotechnology
PBYI
$401M
$8.87M 0.54%
+101,500
New +$5.68M
PRQR icon
46
ProQR Therapeutics
PRQR
$255M
$8.3M 0.51%
1,596,275
+43,050
+3% +$214K
NVTA
47
DELISTED
Invitae Corporation
NVTA
$7.76M 0.47%
812,240
– –
CBIO
48
Crescent Biopharma
CBIO
$585M
$6.69M 0.41%
+5,996
New +$4.95M
MEDP icon
49
Medpace
MEDP
$15.1B
$6.53M 0.4%
+225,040
New +$6.31M
CTLT
50
DELISTED
CATALENT, INC.
CTLT
$5.12M 0.31%
145,963
-478,037
-77% -$15.7M
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2017 Portfolio in Review

As of Q2 2017, Redmile Group held 76 positions worth $1.64B, up 6.6% from $1.54B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group's Q2 2017 filing shows 16 new, 22 increased, 20 reduced and 12 closed positions. Its largest new stake was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M. The largest sale was Puma Biotechnology, an estimated $48.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2017 buy was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M.
  • Redmile Group added most to Array Biopharma Inc in Q2 2017, an estimated $27.2M increase.
  • Redmile Group's biggest Q2 2017 reduction was Puma Biotechnology, cutting an estimated $48.4M.
  • Redmile Group fully exited Incyte in Q2 2017, selling an estimated $41.1M.
  • Redmile Group's ten largest holdings make up 45% of its $1.64B portfolio in Q2 2017.
  • Redmile Group opened 16 new positions and closed 12 in Q2 2017.
  • Redmile Group's portfolio value rose 6.6% quarter-over-quarter to $1.64B.

Based on Redmile Group's 13F filing for Q2 2017, filed 15 Aug 2017.